Skip to main content

Karl Hecker Leaves Invitrogen for PerkinElmer; Mike Story Joins Protein Discovery SAB; BioFocus Stone and McMillan to Galapagos Board; and Others

PerkinElmer has named Karl Hecker the new director of R&D for its Boston-based Center of Excellence, the company said yesterday.

 

Hecker joins PerkinElmer from Invitrogen and brings more then 20 years of scientific experience in chemistry and biochemistry applications. He holds a PhD in biochemistry from Florida State University, a MS in chemistry from Eastern Illinois University, and master's and BS degrees in chemistry from Johann Wolfgang Goethe University, Frankfurt Germany.


 

Mike Story has joined Protein Discovery's scientific advisory board, the company said yesterday.

 

Story co-designed the first commercial mass spectrometry system based on quadruple technology and was a co-founder of Finnigan. He is a graduate of UC Berkeley with a BS in chemistry and currently is a director of Syagen Technology.

 


Galapagos named David Stone and Geoff McMillan to its non-executive board today.

 

Stone is currently chairman of Cambridge Biostability and non-executive chairman of Cambridge Sensors. He has previously held positions at BioFocus (of which he is a founder) and Wellcome Research Labs.

 

McMillan is non-executive director of Maelor. He has had positions at BioFocus and Elan and served on the board of Xenova Group and Roche's pharmaceutical division.

 


Richard Delateur was named chief financial officer of Fluidigm, the company said last week.

 

DeLateur comes from Intel, where his most recent position was general manager of new business investments. In his 20 years at Intel, DeLateur worked in the worldwide technology and manufacturing group and in the architecture business group.

 


Genetix named Andrew Kellett finance director effective March 27, the company announced last week.

 

Kellett succeeds Gary Corsi, who leaves the company on January 31.

 

Kellett is currently a finance director at Quest Diagnostics, where he has worked since February 2000. He has also held senior financial positions with MDC, General Cable, and United Biscuits.

 


Peter Tolias stepped down as vice-president at Ortho-Clinical Diagnostics on January 6, GenomeWeb News learned last week. He said he would be taking time off before starting his next position, which he did not disclose.

 

Prior to Ortho-Clinical, Tolias was a director at the Center for Applied Genomics at the Public Health Research Institute in New Jersey. He helped found the center in January 2000.

 


Mary Lipscomb was elected chairman of the board of directors of the National Center for Genome Resources, the NCGR announced today. Lipscomb's position was effective Nov. 19, 2005, according to the statement.

 

Lipscomb is chair of the University of New Mexico's department of pathology. She replaces Miguel Rios, who was appointed chairman emeritus.

 

In addition, NCGR announced the elections to the board of the following:

Donald Armstrong, member emeritus of Memorial Sloan-Kettering Cancer Center; Charles Arntzen, co-director of the Center for Infectious Diseases and Vaccinology at Arizona State University; William Beavis, chief scientific officer of NCGR; Michael Cawley, president and CEO of the Samuel Roberts Noble Foundation in Ardmore, Okla; Mark Chandler, chairman and CEO of Biophysical Corp., in Austin; Keith Joiner, dean of University of Arizona's college of medicine; Stuart Kauffman, director of the Institute for Biocomplexity and Informatics at the University of Calgary; Stephen Kingsmore, CEO of NCGR; Teresa Leger de Fernandez of Nordhaus Law Firm in Santa Fe; Rick Lyons of University of New Mexico's Center for Infectious Disease and Immunity; Michael Martin, president of New Mexico State University in Las Cruces, N.M.; Marvin Miller, chairman of Onconova Therapeutics in Livingston, NJ; Van Romero, vice president for research at New Mexico Tech in Socorro, NM; Gloria Sarto, director of the University of Wisconsin Center for Women's Health; Jon Soderstrom, managing director of the Office of Cooperative Research at Yale University; and Terry Yates, vice president or research and economic development at the University of New Mexico.

 


Lawrence Murphy has joined the board of directors of Third Wave Technologies, the company said today.

 

Murphy has been an independent consultant since 1997 advising Jabil, Nokia, Cisco, Hewlett-Packard and other clients, said the statement.

 

Murphy has also served as executive vice president of Core Industries, a publicly held manufacturing company. 


 Promoted? Changing jobs?GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

 

 

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.